tiprankstipranks
Trending News
More News >

Neurotech’s NTI164 to be Highlighted at Rett Syndrome Scientific Meeting

Story Highlights
Neurotech’s NTI164 to be Highlighted at Rett Syndrome Scientific Meeting

Don’t Miss TipRanks’ Half-Year Sale

The latest update is out from Neurotech International ( (AU:NTI) ).

Neurotech International announced that its lead product, NTI164, will be featured at the International Rett Syndrome Foundation Scientific Meeting. The presentations, led by Professor Carolyn Ellaway, will highlight the positive outcomes of NTI164 in treating Rett Syndrome, showcasing its potential impact on the treatment landscape for this condition. This event represents a significant opportunity for Neurotech to strengthen its position in the biopharmaceutical industry, particularly in the field of pediatric neurological disorders.

More about Neurotech International

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on developing treatments for pediatric neurological disorders. The company is known for its broad-spectrum oral cannabinoid drug therapy, NTI164, which has shown significant clinical benefits in trials for Autism Spectrum Disorder (ASD), PANDAS/PANS, and Rett Syndrome. Neurotech is also exploring treatments for spastic cerebral palsy.

Average Trading Volume: 814,156

Technical Sentiment Signal: Sell

Current Market Cap: A$19.94M

Learn more about NTI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1